Published • loading... • Updated
Vertex Buys Crinetics for $10 Billion, Adding Approved Hormone Disorder Drug
The deal adds Palsonify and a Phase 3 rare-disease drug as Vertex seeks to broaden beyond its cystic fibrosis franchise.
- On Monday, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the San Diego-based endocrinology company at roughly $10 billion.
- Vertex is seeking to diversify beyond its core cystic fibrosis business, which has anchored the company for decades, by zeroing in on serious specialty diseases to fortify its drug pipeline.
- Through the acquisition, Vertex gains Palsonify, approved by the U.S. Food and Drug Administration in September 2025 for acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia; combined, these assets could generate more than $5 billion in peak annual revenue.
- To fund the $10 billion purchase, Vertex secured $4.5 billion in committed bridge financing from Bank of America and Morgan Stanley, though Stifel analyst Paul Matteis wrote that investors are debating whether Vertex "paid full price or even a rich price."
- Pending regulatory and shareholder approval, the deal is expected to close in the third quarter of 2026, as Vertex faces competition from Neurocrine Biosciences' drug Crenessity in the endocrine market.
Insights by Ground AI
19 Articles
19 Articles
Coverage Details
Total News Sources19
Leaning Left2Leaning Right1Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
L 18%
C 73%
Factuality
To view factuality data please Upgrade to Premium
